Libtayo

(Cemiplimab)

Phase 3Monoclonal antibody

Cemiplimab is used to treat certain types of skin cancer, including cutaneous squamous cell carcinoma and melanoma. It works by helping the immune system recognize and fight cancer cells.[1] Libtayo is currently being investigated across 70 indications[3], with its most advanced program in Phase 3.[1]

Libtayo is one of 1082 biologic programs targeting Glioma. It is currently in Phase 3.

Indications

174

Total Trials

132

Active Trials

1,081

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

HIV InfectionActive, not recruiting

Human Papillomavirus-Related Squamous Cell CarcinomaActive, not recruiting

Merkel Cell Skin CancerActive, not recruiting

Hepatitis B Virus InfectionActive, not recruiting

Erectile DysfunctionActive, not recruiting

LeiomyosarcomaActive, not recruiting

Basal Cell CarcinomaUnknown

Lung CancerUnknown

Cutaneous Squamous Cell CarcinomaUnknown

GliomaPhase 1

Active, not recruiting

HIV InfectionPhase 1

Active, not recruiting

Human Papillomavirus-Related Squamous Cell CarcinomaPhase 2

Active, not recruiting

Merkel Cell Skin CancerPhase 1

Active, not recruiting

Hepatitis B Virus InfectionPhase 1

Active, not recruiting

Erectile DysfunctionPreclinical

Active, not recruiting

LeiomyosarcomaPhase 2

Active, not recruiting

Basal Cell CarcinomaPreclinical

Unknown

Lung CancerPreclinical

Unknown

Cutaneous Squamous Cell CarcinomaPreclinical

Unknown

Showing 10 of 70 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Libtayo

Regeneron

Phase 3

3 2

Halaven

Eisai

Preclinical

38 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

DATROWAY

Daiichi Sankyo

Preclinical

4 5

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 6

Chantix

PPrism Pharmaceuticals

Preclinical

1 7

Nubain

AAultman Health Foundation

Preclinical

1 8

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 9

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

1 10

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Lymphoma

NCT06022029

Recruiting

Erectile Dysfunction

NCT06532149

Q4 2026

Phase 2Active, not recruiting

Skin Cancer

NCT05574101

Phase 2Active, not recruiting

Multiple Myeloma

NCT05669989

Phase 2Active, not recruiting

Melanoma

NCT04291105

Phase 1/2Active, not recruiting

Glioblastoma

NCT03491683

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer18 trials

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

Recruiting·MMayo Clinic·Phase 2·NCT06918132·60 enrolled

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Active, not recruiting· Regeneron logo

Regeneron·Phase 2/3·NCT05800015·950 enrolled

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Active, not recruiting·SServier Bio-Innovation LLC·Phase 1/2·NCT06162572·100 enrolled

Show 15 more trials

Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer

Not yet recruiting·—·N/A·NCT06743581·24 enrolled

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Withdrawn·—·Phase 2·NCT05840770

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Active, not recruiting· Regeneron logo

Regeneron·Phase 2·NCT05557591·51 enrolled

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Recruiting· BioNTech logo

BioNTech·Phase 1·NCT05142189·280 enrolled

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Recruiting·SSWOG Cancer Research Network·Phase 2/3·NCT06616584·378 enrolled

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Active, not recruiting· Regeneron logo

Regeneron·Phase 2·NCT06161441·195 enrolled

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

Recruiting·NNitin Ohri·Phase 2·NCT06865339·76 enrolled

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Recruiting·EEmory University·Phase 2·NCT06731270·20 enrolled

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05704634·56 enrolled

Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Terminated· Regeneron logo

Regeneron·Phase 1·NCT03580694·17 enrolled

Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

Not yet recruiting·HHenry Ford Health System·Phase 2·NCT07450183·33 enrolled

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

Not yet recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT07001618·162 enrolled

A Randomized Phase 2 Platform Study to Evaluate Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for the Perioperative Treatment of Patients With Resectable Non-Small Cell Lung Cancer

Recruiting· Regeneron logo

Regeneron·Phase 2·NCT06465329·120 enrolled

A Randomised Phase III Trial of Adjuvant Cemiplimab in Patients With Resected Stage II-IIIA NSCLC Who Have Not Received Prior Adjuvant Chemotherapy

Recruiting·EETOP IBCSG Partners Foundation·Phase 3·NCT06931717·390 enrolled

An Observational Study to Assess the Effectiveness and Safety of Cemiplimab Based Regimen in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe (CEMI-LUNG)

Recruiting· Regeneron logo

Regeneron··NCT05363319·500 enrolled

Cutaneous Squamous Cell Carcinoma9 trials

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Active, not recruiting· Regeneron logo

Regeneron·Phase 3·NCT03969004·415 enrolled

Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma

Not yet recruiting·MMelanoma and Skin Cancer Trials Limited·Phase 2·NCT06418724·27 enrolled

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Terminated·EExicure, Inc.·Phase 1/2·NCT03684785·57 enrolled

Show 6 more trials

Deep sequencIng in Cutaneous Squamous CEll caRciNomas

Active, not recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT05878288·11 enrolled

Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

No longer available· Regeneron logo

Regeneron··NCT03492489

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

Completed· Regeneron logo

Regeneron·Phase 2·NCT04154943·79 enrolled

Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

Withdrawn· Regeneron logo

Regeneron·Phase 2·NCT06384820

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

Completed· Regeneron logo

Regeneron·Phase 1·NCT03889912·97 enrolled

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Completed· Regeneron logo

Regeneron·Phase 2·NCT02760498·432 enrolled

Melanoma6 trials

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

Active, not recruiting· Regeneron logo

Regeneron·Phase 2·NCT06190951·151 enrolled

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06594991·88 enrolled

A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

Completed· BioNTech logo

BioNTech·Phase 2·NCT04526899·184 enrolled

Show 3 more trials

A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT06246916·560 enrolled

Phase 2 Trial of Voyager VI (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination With Cemiplimab in Patients With Select Solid Tumors

Active, not recruiting·VVyriad, Inc.·Phase 2·NCT04291105·87 enrolled

A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma

Active, not recruiting· Regeneron logo

Regeneron·Phase 3·NCT05608291·1,564 enrolled

Skin Cancer5 trials

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Terminated· Sanofi logo

Sanofi·Phase 1/2·NCT04913220·46 enrolled

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

Active, not recruiting·UUniversity of Southern California·Phase 2·NCT04315701·35 enrolled

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05574101·34 enrolled

Show 2 more trials

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

Active, not recruiting·RReplimune Inc.·Phase 2·NCT04050436·231 enrolled

Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.

Recruiting·IInstituto de Investigación Biomédica de Salamanca··NCT07064330·30 enrolled

Squamous Cell Carcinoma5 trials

Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma

Active, not recruiting·UUnknown Sponsor·Phase 2·NCT04632433·25 enrolled

Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Enrolling by invitation·KKrzysztof Misiukiewicz·Phase 1·NCT05376553·24 enrolled

A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

Not yet recruiting·UUniversity of Chicago·Phase 2·NCT07346196·90 enrolled

Show 2 more trials

Randomized Phase III Trial of Neoadjuvant Immunotherapy With Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma (C-PRE)

Suspended·NNational Cancer Institute (NCI)·Phase 3·NCT06568172·420 enrolled

Neoadjuvant Chemotherapy With or Without Cemiplimab (REGN2810) in Sinonasal Squamous Cell Carcinoma: A Randomized Phase 2 Study

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07281417·108 enrolled

95 more indications

Basal Cell Carcinoma4 trials

Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma

Recruiting·IInstituto Oncológico Dr Rosell·Phase 1/2·NCT07251413·18 enrolled

Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

Recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT06981325·34 enrolled

Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

Recruiting·TThomas Jefferson University·Phase 2·NCT05929664·70 enrolled

Show 1 more trial

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Completed· Regeneron logo

Regeneron·Phase 2·NCT03132636·138 enrolled

Advanced Solid Tumors4 trials

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Recruiting·AAnkyra Therapeutics, Inc·Phase 1·NCT06171750·97 enrolled

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

Recruiting·BBiohaven Therapeutics Ltd.·Phase 1/2·NCT06384807·500 enrolled

LAG3 PET Imaging in Advanced Solid Tumors

Active, not recruiting·UUniversity Medical Center Groningen·Phase 1/2·NCT04706715·41 enrolled

Show 1 more trial

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Active, not recruiting·RRakuten Medical, Inc.·Phase 1/2·NCT04305795·23 enrolled

Breast Cancer3 trials

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

Recruiting·—·Phase 2·NCT06860815·11 enrolled

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT01042379·5,000 enrolled

Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer

Active, not recruiting·MMedical College of Wisconsin·Phase 2·NCT04243616·36 enrolled

Lung Cancer3 trials

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Recruiting·VVanderbilt-Ingram Cancer Center·Phase 1/2·NCT05501665·25 enrolled

Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels

Not yet recruiting·UUNICANCER·Phase 2·NCT07360743·275 enrolled

Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

Recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT06656598·152 enrolled

Colorectal Cancer3 trials

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

Not yet recruiting·NNSABP Foundation Inc·Phase 2·NCT07058012·79 enrolled

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT06205836·44 enrolled

Combining Capecitabine/Oxaliplatin Chemotherapy With Cemiplimab Alone or in Combination With Fianlimab or REGN7075 for the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT07281768·66 enrolled

Advanced Malignancies3 trials

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Terminated·BBolt Biotherapeutics, Inc.·Phase 1·NCT06052852·17 enrolled

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

Active, not recruiting· Regeneron logo

Regeneron·Phase 1·NCT03233139·146 enrolled

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Completed· Regeneron logo

Regeneron·Phase 1·NCT02383212·398 enrolled

Prostate Cancer3 trials

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Terminated· BioNTech logo

BioNTech·Phase 1/2·NCT04382898·75 enrolled

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

Recruiting· Regeneron logo

Regeneron·Phase 1/2·NCT05125016·370 enrolled

Phase I/II Trial of Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Active, not recruiting·UUniversity of Wisconsin, Madison·Preclinical·NCT04989946·57 enrolled

Ovarian Cancer3 trials

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Recruiting· Regeneron logo

Regeneron·Phase 1/2·NCT03564340·890 enrolled

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Recruiting· Regeneron logo

Regeneron·Phase 1·NCT06469281·90 enrolled

Multi-Arm Phase 2 Platform Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer

Recruiting· Regeneron logo

Regeneron·Phase 2·NCT06787612·220 enrolled

Renal Cell Carcinoma3 trials

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Active, not recruiting·SSillaJen, Inc.·Phase 1/2·NCT03294083·89 enrolled

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

Recruiting·UUniversity of Oklahoma·Phase 2·NCT07223541·72 enrolled

A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06699602·10 enrolled

Solid Tumor3 trials

A Phase 1, Multicenter, Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination With Other Anti-Cancer Agents in Adult Participants With Advanced or Metastatic Solid Tumors

Recruiting·BBiohaven Therapeutics Ltd.·Phase 1·NCT06874335·140 enrolled

Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06651593·40 enrolled

A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Active, not recruiting· Regeneron logo

Regeneron·Preclinical·NCT04626635·548 enrolled

Monoclonal2 trials

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Unknown status·OOncoResponse, Inc.·Phase 1/2·NCT05094804·172 enrolled

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Recruiting·OOncoResponse, Inc.·Phase 1/2·NCT06090266·168 enrolled

Lymphoma2 trials

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Recruiting·OOncoNano Medicine, Inc.·Phase 1·NCT06022029·168 enrolled

Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

Withdrawn· Regeneron logo

Regeneron·Phase 2·NCT04373083

Thyroid Cancer2 trials

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT06902376·12 enrolled

A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07470489·12 enrolled

Squamous Cell Cancer2 trials

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

Recruiting·EEmory University·Phase 1·NCT04428671·20 enrolled

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03565783·44 enrolled

Neoadjuvant2 trials

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06855212·21 enrolled

TOP 2301: Neoadjuvant Chemo for NSCLC

Suspended·—·Phase 2·NCT06385262·126 enrolled

Glioblastoma2 trials

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Active, not recruiting· Inovio Pharmaceuticals logo

Inovio Pharmaceuticals·Phase 1/2·NCT03491683·52 enrolled

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT07422363·30 enrolled

Metastatic NSCLC2 trials

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Recruiting·MMaia Biotechnology·Phase 3·NCT06908304·300 enrolled

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Not yet recruiting·SSwiss Cancer Institute·Phase 2·NCT07020065·156 enrolled

Maintenance Therapy2 trials

A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.

Recruiting·FFondazione Ricerca Traslazionale·Phase 2·NCT07264673·160 enrolled

A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER

Not yet recruiting·HHospital Israelita Albert Einstein·Phase 2·NCT07101848·42 enrolled

Advanced NSCLC2 trials

Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC

Active, not recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT05401786·54 enrolled

THIO Sequenced With Cemiplimab in Advanced NSCLC

Recruiting·MMaia Biotechnology·Phase 2·NCT05208944·227 enrolled

Resectable NSCLC2 trials

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 1/2·NCT06088771·21 enrolled

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Active, not recruiting· Regeneron logo

Regeneron·Phase 2·NCT03916627·65 enrolled

Glioma2 trials

ASP8374 + Cemiplimab in Recurrent Glioma

Completed·—·Phase 1·NCT04826393·14 enrolled

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Terminated· Regeneron logo

Regeneron·Phase 1/2·NCT03690869·57 enrolled

Cervical Cancer2 trials

Study of Cemiplimab in Adults With Cervical Cancer

Completed· Regeneron logo

Regeneron·Phase 3·NCT03257267·608 enrolled

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Completed· Regeneron logo

Regeneron·Phase 2·NCT04646005·113 enrolled

Head and Neck Cancer2 trials

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04722523·40 enrolled

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06980038·44 enrolled

Multiple Myeloma2 trials

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT05669989·70 enrolled

Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma

Recruiting· Regeneron logo

Regeneron·Phase 1·NCT05137054·317 enrolled

Blood-Brain Barrier1 trial

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

Recruiting·IInSightec·Phase 3·NCT05317858·30 enrolled

Acute Lymphoblastic Leukemia1 trial

Cemiplimab in AlloSCT/SOT Recipients With CSCC

Completed·—·Phase 1/2·NCT04339062·12 enrolled

Survivorship1 trial

CemiplimAb Survivorship Epidemiology

Completed· Regeneron logo

Regeneron··NCT03836105·287 enrolled

Bladder Cancer1 trial

Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

Recruiting·—·Phase 2·NCT06571708·36 enrolled

Women1 trial

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Recruiting· Regeneron logo

Regeneron·Phase 1/2·NCT04590326·612 enrolled

Unresectable1 trial

Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma

Recruiting·NNorthwestern University·Phase 2·NCT07050186·15 enrolled

Leiomyosarcoma1 trial

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Recruiting·GGabriel Tinoco·Phase 2·NCT06528769·16 enrolled

Colon Cancer1 trial

The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05961709·50 enrolled

Unresectable Solid Tumor1 trial

SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT04729725·3 enrolled

HBV1 trial

Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT04046107

Randomized1 trial

A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Unknown status·IISA Pharmaceuticals·Phase 2·NCT03669718·194 enrolled

PD-1 Inhibitors1 trial

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Unknown status·SSilverback Therapeutics·Phase 1·NCT04460456·58 enrolled

Solid Cancers1 trial

A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

Recruiting· Regeneron logo

Regeneron·Phase 1·NCT05259709·50 enrolled

Maintenance Treatment1 trial

Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer

Recruiting·AAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia·Phase 2·NCT07085572·31 enrolled

Acute Myeloid Leukemia1 trial

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Recruiting·MMayo Clinic·Phase 1·NCT03017820·127 enrolled

Metastatic Colon Cancer1 trial

Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer

Not yet recruiting·JJohn Strickler, M.D.·Phase 2·NCT07224022·24 enrolled

Papilloma1 trial

A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment

Not yet recruiting·UUniversity of Chicago·Phase 2·NCT07179315·68 enrolled

PD-1antibody1 trial

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Active, not recruiting·HHotSpot Therapeutics, Inc·Phase 1/2·NCT05662397·77 enrolled

Metastatic1 trial

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Active, not recruiting·UUniversity of Southern California·Phase 1·NCT04387084·10 enrolled

mCRPC1 trial

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06826768·60 enrolled

Efficacy1 trial

Comparative Efficacy of Cemiplimab to Historical Standard of Care in France

Completed· Sanofi logo

Sanofi··NCT05302297·305 enrolled

Antibody-Drug Conjugate1 trial

Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Terminated· Regeneron logo

Regeneron·Phase 1·NCT04982224·30 enrolled

SMARCB1-Deficient Malignancies1 trial

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06444880·40 enrolled

Dedifferentiated Liposarcoma1 trial

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 2·NCT05694871·77 enrolled

Pancreatic Cancer1 trial

Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04177810·25 enrolled

Biomarker1 trial

Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial

Not yet recruiting·UUniversità Vita-Salute San Raffaele·Phase 2·NCT07274384·74 enrolled

Pancreatic Adenocarcinoma1 trial

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Recruiting·GGulam Manji·Phase 2·NCT04543071·10 enrolled

Relapsed or Refractory1 trial

Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy

Recruiting·WWon Seog Kim·Phase 2·NCT04763616·37 enrolled

Refractory Tumor1 trial

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Not yet recruiting·MMohammed Milhem·Phase 1·NCT07404332·35 enrolled

Pleural Mesothelioma1 trial

Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma

Not yet recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT07234058·126 enrolled

Cancer1 trial

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

Recruiting· Regeneron logo

Regeneron·Phase 1/2·NCT06413680·240 enrolled

Patients With Solid Tumors1 trial

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Approved for marketing· Regeneron logo

Regeneron··NCT06132191

Metastatic Cancer1 trial

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Terminated· Regeneron logo

Regeneron·Phase 2·NCT04916002·77 enrolled

Immunotherapy1 trial

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Recruiting·WWeill Medical College of Cornell University·Phase 2·NCT06623656·112 enrolled

Patients With Advanced Solid Tumors1 trial

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Active, not recruiting·SSensei Biotherapeutics, Inc.·Phase 1/2·NCT05864144·98 enrolled

Erectile Dysfunction1 trial

ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS··NCT06532149·80 enrolled

Advanced1 trial

Anti-PD1-antibody and Pulsed HHI for Advanced BCC

Active, not recruiting·RReinhard Dummer·Phase 2·NCT04679480·20 enrolled

Penile Cancer1 trial

A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER

Not yet recruiting·HHospital Israelita Albert Einstein·Phase 2·NCT07101822·42 enrolled

Immune1 trial

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

Completed·PPalleon Pharmaceuticals, Inc.·Phase 1/2·NCT05259696·69 enrolled

Non-squamous NSCLC1 trial

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Active, not recruiting· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1/2·NCT05882734·61 enrolled

Hepatocellular Carcinoma1 trial

Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma

Not yet recruiting·VVirginia Commonwealth University·Phase 1·NCT07365839·20 enrolled

B-cell Malignancies1 trial

A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

Active, not recruiting· Regeneron logo

Regeneron·Phase 1·NCT02651662·105 enrolled

Solid Tumor Malignancies1 trial

Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

Terminated· Regeneron logo

Regeneron·Phase 1·NCT04465487·38 enrolled

Uveal Melanoma1 trial

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06121180·32 enrolled

ctDNA1 trial

PALACE: Cemiplimab Trial According to ctDNA Levels

Recruiting·FFundación GECP·Phase 2·NCT06917573·63 enrolled

Cutaneous T-cell lymphoma1 trial

BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma

Withdrawn·AAHS Cancer Control Alberta·Phase 1/2·NCT05538988

Biliary Tract Cancer1 trial

Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)

Recruiting·—·Phase 2·NCT07433673·20 enrolled

Completed· Regeneron logo

Regeneron·Phase 1·NCT03005782·333 enrolled

Metastatic Melanoma1 trial

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Active, not recruiting· Regeneron logo

Regeneron·Phase 3·NCT05352672·1,546 enrolled

Oropharynx Squamous Cell Carcinoma1 trial

Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05535023

Angiosarcoma1 trial

Cemiplimab for Secondary Angiosarcomas

Completed·RRadboud University Medical Center·Phase 2·NCT04873375·18 enrolled

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v81 trial

A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients With Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07195734·180 enrolled

Metastatic Castration-resistant Prostate Cancer, mCRPC1 trial

A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression

Recruiting· Regeneron logo

Regeneron·Preclinical·NCT03972657·345 enrolled

Cutaneous Squamous Cell Carcinoma (CSCC)1 trial

A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC)

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT06585410·369 enrolled

Adrenal Cortical Carcinoma1 trial

A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06900595·48 enrolled

Advanced Renal Cell Carcinoma (aRCC)1 trial

A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Recruiting·BBrian Rini·Phase 2·NCT07188896·120 enrolled

Hormone-receptor-positive Breast Cancer1 trial

A Phase I Trial of Capecitabine in Combination With Cemiplimab in Patients With Hormone Receptor Positive Metastatic Breast Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT05064085·13 enrolled

Advanced Non-Small Cell Lung Cancer1 trial

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%

Active, not recruiting· Regeneron logo

Regeneron·Preclinical·NCT05785767·149 enrolled

Peripheral T-Cell Lymphoma1 trial

MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

Recruiting·MMayo Clinic·Phase 1·NCT06508463·21 enrolled

Metastatic Colorectal Adenocarcinoma1 trial

A Phase 1 and Randomized Phase 2 Trial of Pidnarulex (CX-5461) and Cemiplimab (REGN2810) in Refractory Microsatellite Stable Colorectal Cancer

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT07147231·86 enrolled

Metastatic Colorectal Cancer1 trial

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT06412198·31 enrolled

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v81 trial

A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting·MMarcelo Bonomi·Phase 2·NCT04862650·46 enrolled

Carcinoma，Non-Small-Cell Lung1 trial

A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer

Completed· Regeneron logo

Regeneron·Phase 3·NCT03088540·712 enrolled

Head and Neck Squamous Cell Carcinoma (HNSCC)1 trial

Phase II Randomized Study of Fianlimab Plus Cemiplimab Versus Cemiplimab Plus Placebo in First-Line Treatment of Participants With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Is Positive for PD-L1 Expression

Recruiting· Regeneron logo

Regeneron·Phase 2·NCT06769698·120 enrolled

Locally Recurrent Oral Cavity Squamous Cell Carcinoma1 trial

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06448026·17 enrolled

Bladder Urothelial Carcinoma1 trial

Neoadjuvant STereotActic Body Radiotherapy and Cemiplimab With or Without Fianlimab for Cisplatin-Ineligible or Cisplatin-Declining Patients With Muscle-Invasive Bladder Cancer (NeoSTAR Bladder)

Not yet recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07414992·44 enrolled

NSCLC Stage IV1 trial

Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC

Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT06219317·136 enrolled

Lung Non-Small Cell Carcinoma1 trial

Phase II Trial: Photoimmunotherapy and Anti-PD1 in Patients With Refractory Inoperable and Metastatic Non-Small Cell Lung Cancer

Not yet recruiting·RRoswell Park Cancer Institute·Phase 2·NCT06943664·27 enrolled

Merkel Cell Carcinoma, Stage I1 trial

Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab - A Randomized, Double-blind, Placebo-controlled, Non-comparative Phase II Study

Recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT07387198·135 enrolled

Sources

References

[1]
ClinicalTrials.gov — 174 trial records for Cemiplimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cemiplimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cemiplimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Programmed Cell Death Protein 1 Inhibitor[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Regeneron